Wilcock, Gordon KGauthier, SergeFrisoni, Giovanni BJia, JianpingHardlund, Jiri HMoebius, Hans JBentham, PeterKook, Karin ASchelter, Bjoern OlafWischik, Damon JDavis, Charles SStaff, Roger TVuksanovic, VesnaAhearn, TrevorBracoud, LucShamsi, KohkanMarek, KenSeibyl, JohnRiedel, GernotStorey, John M. D.Harrington, Charles RWischik, Claude M2017-12-062017-12-062017-11-28Wilcock, G K, Gauthier, S, Frisoni, G B, Jia, J, Hardlund, J H, Moebius, H J, Bentham, P, Kook, K A, Schelter, B O, Wischik, D J, Davis, C S, Staff, R T, Vuksanovic, V, Ahearn, T, Bracoud, L, Shamsi, K, Marek, K, Seibyl, J, Riedel, G, Storey, J M D, Harrington, C R & Wischik, C M 2017, 'Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease : Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial', Journal of Alzheimer's Disease, vol. 61, no. 1, pp. 435-457. https://doi.org/10.3233/JAD-1705601387-2877ORCID: /0000-0002-5261-5467/work/73579133ORCID: /0000-0003-2250-3920/work/47672895http://hdl.handle.net/2164/9693The supplementary material is available in the electronic version of this article: http://dx.doi.org/10.3233/JAD-170560. The study was sponsored by TauRx Therapeutics (Singapore). We thank Lon Schneider and Howard Feldman for their contribution to the Scientific Advisory Board. We gratefully acknowledge study investigators and the generosity of study participants. Authors’ disclosures available online (http://j-alz.com/manuscript disclosures/17-0560r3).241832124engADAS-cogAlzheimer’s diseaseamyloid proteinclinical trialcohort studymethylthioniniumtau proteintreatmentRC0321 Neuroscience. Biological psychiatry. NeuropsychiatryRC0321Journal article10.3233/JAD-170560https://www.j-alz.com/vol61-1611